__NUXT_JSONP__("/drugs/Siplizumab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"288392-69-8",chebiId:b,chemicalFormula:b,definition:"A humanized monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth.",fdaUniiCode:"KUW1QG1ZM3",identifier:"C38685",preferredName:a,semanticType:"Immunologic Factor",subclassOf:["C20401"],synonyms:["Immunoglobulin G1, Anti-(human CD2 (Antigen))(Human-rat Monoclonal MEDI-507 G1-chain), Disulfide with Human-rat Monoclonal MEDI-507 Light Chain, Dimer","MEDI-507","SIPLIZUMAB",a,"siplizumab"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FSiplizumab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Siplizumab","","2021-10-30T13:39:34.443Z")));